Casey M Tansey
CIK 1474322 · last filed 2026-07-17
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$482.49M
Companies
13
Total Filings
73
Lifetime Open-Market Net
-$9.97M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| INSP | Director | 27,132 | $50.26 | $1.36M | -$14.14M | 47 | 2026-07-17 |
| SI | Director | 973,842 | $23.31 | $22.70M | $600.0K | 2 | 2026-06-29 |
| HTFL | Director | 3,089,206 | $26.09 | $80.58M | $0 | 2 | 2026-06-18 |
| MOBI | Director | 547,422 | $11.26 | $6.16M | $1000.0K | 1 | 2026-05-11 |
| eFFECTOR Therapeutics, Inc. (EFTRW) Delisted | 10%+ Owner | 136,241 | $0.00 | $82 | -$297.5K | 1 | 2022-05-19 |
| ON24 INC. (ONTF) Delisted | 10%+ Owner | 7,368,405 | $8.10 | $59.68M | $1.50M | 1 | 2021-02-05 |
| ARS Pharmaceuticals, Inc. (SBTX) Delisted | 10%+ Owner | 105,012 | $5.87 | $616.4K | $4.00M | 1 | 2020-12-08 |
| INTERMOLECULAR INC (IMI) Delisted | 10%+ Owner | 0 | — | — | -$34.3K | 1 | 2018-11-13 |
| Intersect ENT, Inc. (XENT) Delisted | Director | 2,546 | $28.24 | $71.9K | $0 | 9 | 2017-06-05 |
| BOX | 10%+ Owner | 11,713,775 | $31.25 | $366.06M | $0 | 1 | 2015-01-30 |
| GWRE | 10%+ Owner | 36,638 | $153.65 | $5.63M | -$2.36M | 3 | 2012-09-25 |
| MXL | 10%+ Owner | 0 | $66.50 | $0 | -$232.6K | 3 | 2012-08-22 |
| IMPERVA INC (IMPV) Delisted | 10%+ Owner | 9,733 | — | — | $0 | 1 | 2011-11-15 |
Recent Filings · Page 3 of 8
73 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2023-07-19 | INSP | Grant (A) | +40 | $13.0K | EDGAR |
| 2023-05-01 | INSP | Grant (A) | +669 | $0 | EDGAR |
| 2023-04-12 | INSP | Grant (A) | +56 | $13.0K | EDGAR |
| 2023-01-19 | INSP | Grant (A) | +52 | $12.9K | EDGAR |
| 2022-10-13 | INSP | Grant (A) | +81 | $13.7K | EDGAR |
| 2022-07-13 | INSP | Grant (A) | +77 | $14.9K | EDGAR |
| 2022-05-19 | eFFECTOR Therapeutics, Inc. (EFTRW) Delisted | Sell (S) | −172,135 | -$297.5K | EDGAR |
| 2022-05-10 | INSP | Grant (A) | — | $0 | EDGAR |
| 2022-04-12 | INSP | Grant (A) | +59 | $15.0K | EDGAR |
| 2022-01-12 | INSP | Grant (A) | +65 | $14.8K | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.